Treatment patterns and clinical outcomes in patients with relapsed/refractory Hodgkin lymphoma receiving stem cell transplantation outside Europe and North America: results from the B-HOLISTIC study

Information on Hodgkin lymphoma (HL) is mostly limited to Europe and North America. Thisreal-world, retrospective study assessed treatment pathways and clinical outcomes in adults withstage IIB–IV classical HL receiving frontline treatment (n¼1598) or relapsed/refractory HL (RRHL,n¼426) in regions outside Europe and North America between January 2010 and December2013. The primary endpoint was progression-free survival (PFS) in the RRHL group. Amongpatients with RRHL, 89.0% received salvage chemotherapy; most common regimen was etopo-side, methylprednisolone, cytarabine, cisplatin (ESHAP; 26.3%). Median PFS in the RRHL groupwas 13.2months (95% confidence interval [CI]: 9.9–20.2) and was longer in patients withvs.with-out stem cell transplantation (SCT; 20.6vs.7.5 months;p¼0.0071). This large-scale study identi-fied a lower PFS for RRHL in the rest of the world compared with Europe and North America,highlighting the need for novel targeted therapies and SCT earlier in the treatment continuum.
This study was funded by Takeda Pharmaceuticals International AG - Singapore Branch.